42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Recommended Citation
Silverberg JI, Deleuran M, Stein Gold LF, Bunick CG, Hijnen DJ, Calimlim BM, Teixeira HD, Platt AM. 42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). J Am Acad Dermatol 2023; 89(3):AB90.
Document Type
Conference Proceeding
Publication Date
9-19-2023
Publication Title
J Am Acad Dermatol
Abstract
Atopic dermatitis (AD) is a debilitating skin disease that impairs quality of life (QoL). We assessed the long-term effect of once daily oral upadacitinib, a selective Janus kinase-1 inhibitor, on patient-reported outcomes through week 52 in the blinded extension periods of Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD Up (NCT03568318) using observed cases analysis. Patients were randomized to upadacitinib 15 mg, upadacitinib 30 mg, or placebo at baseline. At 16 weeks, patients who received placebo were rerandomized to upadacitinib 15 or 30 mg. Patient-reported itch (Worst Pruritus Numerical Rating Scale); skin pain, and symptom severity (AD Symptom Scale); sleep, daily activities, and emotional state (AD Impact Scale); symptom frequency (Patient-Oriented Eczema Measure); and QoL (Dermatology Life Quality Index) were assessed. 2584 randomized patients were included. As early as week 2, a greater proportion of patients receiving upadacitinib achieved clinically relevant itch, sleep, and QoL responses versus placebo. Response rates improved through week 8, with markedly higher response rates with upadacitinib 15 mg (itch: 52.5%-63.7%; sleep: 57.7%-66.7%; QoL: 84.6%-88.1%) and 30 mg (itch: 70.3%-75.4%; sleep: 68.0%-78.5%; QoL: 88.5%-92.5%) versus placebo (itch: 17.4%-19.6%; sleep: 22.1%-26.9%; QoL: 54.1%-65.3%). Improvements were maintained through week 52. Similar patterns were observed for other outcomes. Response rates 4 weeks after switching from placebo to upadacitinib reached similar levels as patients originally randomized to upadacitinib. These results support rapid and sustained efficacy of once daily oral upadacitinib in reducing itch and other AD symptoms and improving sleep and QoL of patients with AD.
Volume
89
Issue
3
First Page
AB90
